Over 200 communicators.
Over 4,000,000 impressions.
Reach Over 250,000 Twitter accounts.
Hundreds of tweets.
1 Transparent Conversation
The Power of a Twitter Chat
Submitted by: Precision Therapeutics
Posted: Sep 07, 2010 – 06:10 PM EST
PITTSBURGH, Sep. 07 /CSRwire/ - /PRNewswire/ - Precision Therapeutics will sponsor the Pittsburgh Chapter of the National Ovarian Cancer Coalition's "Walk to Break the Silence" on Sunday, September 12, 2010.
The walk, which takes place at the North Park Boathouse, is an optional 1 or 5 mile hike to benefit ovarian cancer awareness.
Hoping that a great number of its employees will unite to help fortify the partnerships it has forged in supporting the very cancer patients that it helps physicians treat, Precision has offered to cover the registration fee for any employee who wishes to help make this event a success.
"It is of utmost importance for Precision to support the promotion of ovarian cancer awareness," says Sean McDonald, CEO of Precision. "Our alliance with local and national cancer advocates demonstrates our dedication to the advancement of personalized cancer treatments and offers our employees the ability to support these important organizations."
For more information on the National Ovarian Cancer Coalition, please visit www.ovarian.org.
About Precision Therapeutics
Precision Therapeutics, a life-science company based in Pittsburgh, Pennsylvania, is committed to improving outcomes of cancer patients. Known for their expertise in the live-tissue platform, Precision develops novel markers to help guide treatment decisions based on the biological processes of each individual's cancer.
Precision's state of the art bioinformatics combined with the analysis of the live molecular, proteomic and genomic activity of each patient's cancer offers an innovative foundation for further development and commercialization of novel predictive markers for cancer therapy. Precision's first commercial test, ChemoFx®, is a proprietary drug response marker which measures an individual's malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician. For more information, please visit www.chemofx.com or www.precisiontherapeutics.com.
For more information, please contact: